Dihydro-CDDO-Trifluoroethyl Amide (dh404), a Novel Nrf2 Activator, Suppresses Oxidative Stress in Cardiomyocytes

Tomonaga Ichikawa, Jinqing Li, Colin J. Meyer et al. · 2009

Read Dihydro-CDDO-Trifluoroethyl Amide (dh404), a Novel Nrf2 Activator, Suppresses Oxidative Stress in Cardiomyocytes by Tomonaga Ichikawa, Jinqing Li, Colin J. Meyer et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0008391.txt.

Introduction

Tomonaga Ichikawa and his team wrote in PLOS ONE in 2009 about a shield for heart cells. A cell switch called Nrf2 guards cells from harm done by oxygen stress. Drugs that turn this switch on could help a weak heart that grows stiff and thick with time. But such drug use in the heart and blood system was not yet firm ground. The team made a new compound, dh404, that turns Nrf2 on.

In heart muscle cells, dh404 cut the harm from oxygen stress by a wide mark. Cells kept safe in this way may hold up when the heart is strained. A new switch-turner gives labs a tool to probe this guard path. It may in time lead to new drugs for heart failure.

Catalog record

CREATORTomonaga Ichikawa, Jinqing Li, Colin J. Meyer et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008391

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Dihydro-CDDO-Trifluoroethyl Amide (dh404), a Novel Nrf2 Activator, Suppresses Oxidative Stress in Cardiomyocytes Authors: Tomonaga Ichikawa, Jinqing Li, Colin J. Meyer, Joseph S. Janicki, Mark Hannink, Taixing Cui Published: 2009, PLOS ONE DOI: 10.1371/journal.pone.0008391 ABSTRACT Targeting Nrf2 signaling appears to be an attractive approach for the treatment of maladaptive cardiac remodeling and dysfunction; however, pharmacological modulation of the Nrf2 pathway in the cardiovascular system remains to be established. Herein, we report that a novel synthetic triterpenoid derivative, dihydro-CDDO-trifluoroethyl amide (dh404), activates Nrf2 and suppresses oxidative stress in cardiomyocytes. Dh404 interrupted the Keap1-Cul3-Rbx1 E3 ligase complex-mediated Nrf2 ubiquitination and subsequent degradation saturating the binding capacity of Keap1 to Nrf2, thereby rendering more Nrf2 to be translocated into the nuclei to activate Nrf2-driven gene transcription. A mutant Keap1 protein containing a single cysteine-to-serine substitution at residue 151 within the BTB domain of Keap1 was resistant to dh404-induced stabilization of Nrf2 protein. In addition, dh404 did not dissociate the interaction of Nrf2 with the Keap1-Cul3-Rbx1 E3 ligase complex. Thus, it is likely that dh404 inhibits the ability of Keap1-Cul3-Rbx1 E3 ligase complex to target Nrf2 for ubiquitination and degradation via modifying Cys-151 of Keap1 to change the conformation of the complex. Moreover, dh404 was able to stabilize Nrf2 protein, to enhance Nrf2 nuclear translocation, to activate Nrf2-driven transcription, and to suppress angiotensin II (Ang II)-induced oxidative stress in cardiomyocytes. Knockdown of Nrf2 almost blocked the anti-oxidative effect of dh404. Dh404 activated Nrf2 signaling in the heart. Taken together, dh404 appears to be a novel Nrf2 activator with a therapeutic potential for cardiac diseases via suppressing oxidative stress. INTRODUCTION Triterpenoids, synthesized in many plants, including a large variety of vegetarian foods and medicinal herbs, are widely used as traditional medicine of in Asian countries [1] . More than 20,000 triterpenoids exist in nature [2] . In fact, triterpenoids of oleanolic acid (OA) and ursolic acid (UA) have emerged to be attractive drug scaffolds because they are relatively non-toxic, cytoprotective, hypoglycemic, anti-inflammatory, anti-hyperlipidemic, and anti-tumorigenic [1] . To improve the pharmacological potency, novel derivatives of OA, such as 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO), CDDO methyl ester (CDDO-Me), CDDO imidazolides (CDDO-Im), and CDDO amides (methyl amide, CDDO-MA; ethyl amide, CDDO-EA), have been synthesized [3] . These synthetic derivatives of OA are potent multifunctional molecules in vitro . Depending on the dose, they can suppress inflammation, activate cytoprotective pathways, induce differentiation, inhibit proliferation and induce apoptosis. In fact, they are the most potent anti-inflammatory and anti-carcinogenic triterpenoinds identified [4] . Importantly, CDDO-Me that has been tested in clinical oncology trails is currently in a phase IIb clinical trial for the treatment of chronic kidney diseases. However, the therapeutic potential of synthetic oleanane triterpenoids (SO) in cardiovascular diseases has not been explored. Molecular mechanisms underlying the pleiotropic nature of SO are only partly understood. However; it has been recently demonstrated that activation of nuclear factor-erythroid (NF-E) 2–related factor 2 (Nrf2) signaling is critical for the SO-mediated anti-inflammatory and anti-carcinogenic activities [4] . Nrf2 is a member of the Cap ‘n’ Collar (CNC) family of basic leucine zipper (bZip) transcription factors that includes NF-E2, Nrf1-3 and Bach1-2 [5] – [9] . As other members of the CNC family of bZip transcription factors, Nrf2 forms a heterodimer with its obligatory partner Maf, thereby binding to a cis -acting enhancer sequence known as the antioxidant response element (ARE), also referred to as the electrophile response element (EpRE) with a core nucleotide sequence of 5′-RTGACNNNGC-3′, to regulate the basal and inducible expression of more than 200 genes that can be grouped into several categories including antioxidant genes, phase II detoxifying enzymes, transporters, scavenger receptor, chaperone proteins, transcription factors [10] – [12] . The protein stability and transcriptional activity of Nrf2 is principally regulated by a BTB-Kelch protein, Keap1 that functions as a substrate adaptor for a cullin (Cul)3-dependent E3 ubiquitin ligase complex [10] – [12] . Keap1 targets Nrf2 for ubiquitination and subsequent degradation by the 26S proteasome. Mounting evidence has revealed that Nrf2 is a major regulator of cellular defenses against various pathological stresses in different organs including lung, liver, gastrointestinal tract, bladder, kidney, brain, skin, and ovary. Nrf2 also appears to be an attractive drug target for the treatment or prevention of several human disorders such as pulmonary fibrosis, hepatic and gastrointestinal disease, carcinogenesis and neurodegenerative disease [12] – [23] . Of note, we have recently demonstrated that Nrf2 is a critical negative regulator of pathological cardiac hypertrophy and heart failure via its ability to orchestrate a group of antioxidant genes [24] . These results suggest that targeting Nrf2 signaling might be a novel therapeutic strategy for the treatment of maladaptive cardiac hypertrophy and the prevention of heart failure. Interestingly, a recent report highlighted the fact that the Keap1-Nrf2 system comprises discrete sensor sites, including the Keap1 cysteines Cys-151 and Cys-275, for a variety of Nrf2-activating compounds and special “cysteine codes” are linked with the Nrf2-mediated biological actions [25] . Therefore, a novel class of synthetic SO might activate the Nrf2-driven cardiac protective signaling via modulating “cysteine codes” of Keap1-Nrf2 system. In the present study, we report that a novel triterpenoid derivative of dihydro-CDDO-trifluoroethyl amide (dh404) stabilizes Nrf2 protein via modulating Keap1 Cys-151, thereby activating Nrf2-driven transcriptional activity. In addition, dh404 inhibits the hypertrophic agonist angiotensin II (ANG II)-induced formation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in cardiomyocytes via the activation of Nrf2 signaling. Notably, dh404 activates Nrf2 signaling in the heart. Our results highlight a therapeutic potential of dh404 for the treatment of heart disease. RESULTS It has been well documented that synthetic triterpenoid derivatives are able to activate Nrf2 [4] , therefore, we synthesized a novel triterpenoid derivative of dihydro-CDDO-trifluoroethyl amide that was named dh404 ( Figure 1 ) and investigated the impact of dh404 on Keap1-Nrf2 homeostasis. Firstly, we established a system of Keap1-Nrf2 homeostasis in NIH 3T3 cells that express negligible levels of Nrf2 and Keap1 as previously described [26] . Briefly, different ratios of Keap1 and Nrf2 plasmids were transfected into NIH 3T3 cells. The Nrf2-driven transcriptional activity reached the basal level when the exogenous expression of Nrf2 and Keap1 was achieved in a ratio of 10∶1 (Nrf2:Keap1) ( Figure 2A ). Confocal microscopic analysis clearly indicated that HA-Nrf2 protein was efficiently sequestered in the cytoplasm by the co-expression of CBD-Keap1 protein ( Figure 2B ). Thus, we used the balanced Keap1-Nrf2 expression system in the present study. Secondly, we determined the potential of dh404 to activate Nrf2. As shown in Figure 2B , dh404 triggered Nrf2 nuclear translocation, suggesting that dh404 is able to activate Nrf2. We have previously demonstrated that C273 and C288 which are distinct cysteine residues in Keap1, are required for Keap1-mediated constitutive suppression of Nrf2 activity, and C151, that is required for escape by Nrf2 from Keap1-dependent suppression in response to sulforaphane and oxidative stress [26] . Accordingly, the effect of dh404 on Nrf2 transcriptional activity was determined in the cells transfected with Nrf2, Keap1, and these Keap1 mutants ( Figure 2C ). Dh404 activated Nrf2 transcriptional activity in the cells transfected with Nrf2 and Keap1 but not with Nrf2 and C151S Keap1 mutant, suggesting that dh404 specifically interacts with the Cys-151 residue in Keap1 leading to disruption of

Read the complete text